Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-03-14
2006-03-14
Murphy, Joseph (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220, C435S320100, C435S325000
Reexamination Certificate
active
07012133
ABSTRACT:
The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284746 (1994-02-01), Sledziewski et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5652133 (1997-07-01), Murphy
patent: 5707815 (1998-01-01), Charo et al.
patent: 43 32 256 (1993-09-01), None
patent: 0 475 746 (1992-03-01), None
patent: 0 578 962 (1994-01-01), None
patent: WO 92/01810 (1992-02-01), None
patent: WO 94/05695 (1994-03-01), None
patent: WO 94/11504 (1994-05-01), None
patent: WO 95/31467 (1994-05-01), None
patent: WO 9411504 (1994-05-01), None
patent: WO 94/12635 (1994-09-01), None
patent: WO 94/20142 (1994-09-01), None
patent: WO 94/28931 (1994-12-01), None
patent: WO 95/08576 (1995-03-01), None
patent: WO 97/21812 (1997-06-01), None
patent: WO 97/22698 (1997-06-01), None
patent: WO 96/22371 (1997-07-01), None
patent: WO 97/41154 (1997-11-01), None
Harlow et al. Antibodies a Laboratory Manual, Ch 5, p. 76, Cold Spring Harbor Laboratory, 1988.
Lerner et al. Nature vol. 299, pp. 592-596, 1982.
Yamagami et al. Biochem & Biophy. Res. Comm. vol. 202, No. 2, pp. 1156-1162, 1994.
Springer, Timothy A., “Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm”,Cell, 76:301-314, (1994).
Murphy, Philip M., “The Molecular Biology of Leukocyte Chemoattractant Receptors”,Annu. Rev. Immunol., 12:593-633 (1994).
Baggiolini M., and Dahinden Clemens A., “CC chemokines in allergic inflammation”,Immunology Today, 15(3) :127-133, (1994).
Gerard N.P., and Gerard, C., “The chemotactic receptor for human C5z anaphylatoxin”,Nature, 349:614-617, (1991).
Neote, K., et al., “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemoikne Receptor”,Cell, 72:415-425, (1993).
Gao, J-L., et al., “Structure and Functional Expression of the Human Macrophage Inflammatory Protein 1α/RANTES Receptor”,J. of Exp. Med., 177:1421-1427, (1993).
Charo, I.F., et al., “Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails”,Proc. Natl. Acad. Sci. USA, 91:2752-2756 (1994).
Van Riper, G., et al., “Induction, Characterization, and Functional Coupling of the High Affinity Chemokine Receptor for RANTES and Macrophage Inflammatory Protein-1α upon Differentiation of an Eosinophilic HL-60 Cell Line”,J. of Immunol., 152:4055-4061 (1994).
Bischoff, S.C., et al., “RANTES and related chemokines activate human basophil granulocytes theough different G protein-coupled receptors”,Eur. J. Immunol., 23:761-767, (1993).
Dahinden, C.A., et al., “Monocyte Chemotactic Protein 3 Is a Most Effective Basophil- and Eosinophil-activating Chemokine”,J. Exp. Med., 179:751-756 (1994).
Lefkowitz, R.J., “Turned on to ill effect”,Nature, 365:603-604, (1993).
Clapham, D.E., “Mutations in G Protein-Linked Receptors” Novel Insights on Disease,Cell, 75:1237-1239, (1993).
Ponath, P.D., “C-C Chemokine Receptor 3: Identification of a Major Eosinophil Chemotactic Cytokine Receptor”, In: Conference Schedule for conference entitled “On the Cutting Edge of Anti-Inflammatory Drug Discovery”, (Jan., 1995).
Combadiere, C., et al., “Cloning and Functional Expression of Human Eosinophil CC Chemokine Receptor”,J. of Biol. Chem., 270(27) :16491-16494, (1995).
Combadiere, C., et al.,Correction, “Cloning and functional expression of a human Eosinophil CC Chemokine Receptor”,J. Biol. Chem., 270:30235, (1995).
Post, T.W., et al., “Molecular Characterization of Two Murine Eosinophin β Chemokine Receptors”,J. of Immunol., 155:5299-5305, (1995).
Gao, J-L., and Murphy, P.M., “Cloning and Differential Tissue-specific Expression of Three Mouse β Chemokine Receptor-like Genes, Including the Gene for a Functional Macrophage Inflammatory Protein-1α Receptor”,J. of Biol. Chem., 270(29) :17494-17501, (1995).
Ponath, P.D., et al., “Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils”,J. Exp. Med.,183:2437-2448, (1996).
Daugherty B.L., et al., “Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor”,J. Exp. Med., 183:2349-2354, (1996).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3”,J. of Biol. Chem., 271(13) :7725-7730, (1996).
Jose, P.J., et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation”,J. Exp. Med., 179:881-887, (1994).
Förster, R., et al., “A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA”,Biochem. and Biophys. Res. Comm., 196(3) :1496-1503, (1993).
Ponath, P.D., et al., “cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Properties Suggest a Mechanism for the Selective Recruitment of Eosinophils”,Jour. of Clinical Invest., 97(3) :604-612, (1996).
Chaudhuri, A., et al., “Expression of the Duffy antigen in K562 Cells”,J. Biol. Chem., 269(11) :7835-7838, (1994).
Szigetti, V., and Miller R.H., “A Cell Surface Antigen Expressed by Astrocytes and Their Precursors,”GLIA, 8:20-32 (1993).
Gillaspy, G.E., et al., “Antigenic and Differentiative Heterogeneity Among Human Glioblastomas,”Cancer Letters,68:215-224 (1993).
Lyon, J.A., et al., “Monoclonal Antibody Characterization of the 195-Kilodalton Major Surface Glycoprotein ofPlasmodium falciparumMalaria Schizonts and Merozoites: Identification of Additional Processed Products and a Serotype-Restricted Repetitive Epitope,”J. Immunol., 138(3) :895-901 (1987).
Forssmann, U., et al., “Eotaxin-2, a Novel CC Chemokine that is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes,”J. Exp. Med. 185(12) 2171-2176 (1997).
Heath, H., et al., “Chemokine Receptor Usage by Human Eosinophils,”J. Clin. Invest., 99(2) :178-184 (1997).
Chuntharapai, A. and K. Jin Kim, “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Murphy, P.M. et al., “International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors,”Pharmacol. Rev., 52(1):145-176 (2000).
U.S. Appl. No. 10/2
Gerard Craig J.
Gerard Norma P.
Mackay Charles R.
Ponath Paul D.
Post Theodore W.
Brigham & Women's Hospital
Children's Medical Center Corp.
Hamilton Brook Smith & Reynolds P.C.
Millennium Pharmaceuticals Inc.
Murphy Joseph
LandOfFree
Antibodies to C-C chemokine Receptor 3 Protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to C-C chemokine Receptor 3 Protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to C-C chemokine Receptor 3 Protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605020